A historic milestone achieved by GENFIT

About GENFIT

We are a late-stage biopharmaceutical Company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs.

We are a pioneer in the discovery and development of drugs targeting liver diseases, with a longstanding history and strong scientific heritage spanning more than two decades. Thanks to our expertise in bringing early-stage assets with high potential to late-stage development and to our strong track record to develop long term collaboration and partnerships, today we boast a growing and diversified pipeline of innovative therapeutic and diagnostic solutions

We are a world leader in Acute-on-Chronic Liver Failure (ACLF) and its associated medical complications, with five assets in development based on differentiated mechanisms of action leveraging complementary pathways.

Given the high unmet medical need in this indication, some of these programs may qualify for some of the expedited regulatory pathways provided by health authorities

Photo of the GENFIT building in Loos, France

Our Therapeutic Areas

Our R&D pipeline covers targeted therapeutic areas via seven programs across a variety of development stages (preclinical, Phase 1, Phase 2)

Our Success in PBC

In June 2023, GENFIT and Ipsen announced positive topline 52-week data from the pivotal Phase 3 trial ELATIVE®2 evaluating elafibranor in Primary Biliary Cholangitis (PBC). This asset was discovered and successfully developed by GENFIT. Ipsen is now responsible for regulatory applications and the commercialization of elafibranor, as well as further development and life cycle management.

Ipsen

Our expertise

Data science icon
Regulatory Affairs icon
Market access icon

Our Documentation

image illustrative

Half-Year Business and Financial Report

2024 (at June 30 2024)

: Half-Year Business and Financial Report at June 30, 2024

image illustrative

Extra-Financial Performance Report

2023 (2022 activity)

2022 – URD – GENFIT

image illustrative

Latest Press Releases

https://ir.genfit.com/press-releases

image ESG

Our CSR Commitment

Nos vidéos

Acute-on-Chronic Liver Failure (ACLF) Highlights
Le Journal des biotechs : Pascal Prigent
Portrait collaborateur – Yacine – Biostatisticien

1 At EASL Congress in June 2023 it was announced that nonalcoholic steatohepatitis (NASH) would now be referred to as Metabolic dysfunction-associated steatohepatitis (MASH). Nonalcoholic fatty liver disease (NAFLD) will now be referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). GENFIT is progressively transitioning its documentation over to this new nomenclature and both NASH and MASH terms may appear in our documents during this period
2 GENFIT Communique de presse – 30 juin 2023 : Ipsen et GENFIT annoncent les résultats positifs de l’essai de Phase III ELATIVE® évaluant elafibranor chez des patients atteints de cholangite biliaire primitive, une maladie cholestatique rare du foie